

# Molecular mechanisms of targeted cancer treatments

## Monday 02 December 2019

**09.00**     *Registration & coffee*

**09.30**     **Targeted cancer treatments: the current landscape**

- Hallmarks of cancer cells – choose your target
- Cancer and the immune system

**10.15**     **The main classes of current targeted treatments:**

- Monoclonal antibodies
- Small molecule kinase inhibitors

**10.40**     **Question sheet 1**

**11.00**     *Break*

**11.20**     **Immunotherapy**

- Checkpoint inhibitors
- CAR T cell therapy
- Peptide vaccines and oncolytic viruses

**12.10**     **Question sheet 2**

**12.30**     *Lunch*

**13.15**     **Targeting cell communication pathways**

- Why target cell communication?
- Inhibitors of EGFR and HER2
- B-RAF & MEK inhibitors
- PI3K, AKT & mTOR inhibitors
- Drug resistance mechanisms

**14.30**     *Afternoon break*

**14.50**     **Angiogenesis, PARP & CDK inhibitors**

- Targeting VEGF pathways and angiogenesis
- PARP inhibitors
- CDK inhibitors

**15.30**     **Clinical trials, biomarkers and personalised cancer treatment**

- Clinical trial design and the challenge of immunotherapy endpoints and patterns of response
- Progress in biomarkers and biopsies

**16.00**     *Questions and close*